Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s

Binder MT, Becker E, Wiendl M, Schleier L, Fuchs F, Leppkes M, Atreya R, Neufert C, Atreya I, Neurath M, Zundler S (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Inflammatory Bowel Diseases Wiley

Book Volume: 24

Pages Range: 1237-1250

Journal Issue: 6

DOI: 10.1093/ibd/izy077

Abstract

Background: Although anti-adhesion therapies are a novel mainstay in the treatment of inflammatory bowel diseases (IBDs), the mechanisms controlling integrin-dependent gut homing are poorly elucidated, and the available techniques for translational functional investigations are limited. Methods: We used dynamic adhesion assays to study adhesion of CD4+ T cells, CD8+ T cells, CD19+ B cells, and granulocytes to the addressins MAdCAM-1, VCAM-1, and ICAM-1. The effects of vedolizumab, natalizumab, etrolizumab-s, anti-CD11a, and anti-CD18 antibodies were explored. Results: Adhesion of peripheral blood leukocytes from IBD patients and control donors could be validly assessed, and integrin-mediated addressin adhesion could be specifically inhibited by anti-integrin antibodies. Numbers of adhering cells were partly, but not completely, related to integrin expression. Vedolizumab and etrolizumab-s resulted in similar reduction of adhesion to MAdCAM-1, and preliminary data proposed an association of dynamic adhesion to MAdCAM-1 with response to vedolizumab therapy. Conclusions: Dynamic adhesion assays are an easy and broadly applicable method for IBD research that is useful for future translational studies and potentially also for supporting clinical treatment decisions. 10.1093/ibd/izy077_video1izy077_Video_15786486962001.

Authors with CRIS profile

Maximilian Wiendl Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Florian Fuchs Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur) Clemens Neufert Medizinische Fakultät Markus Neurath Lehrstuhl für Innere Medizin I Sebastian Zundler Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Additional Organisation(s)

Interdisziplinäres Zentrum für Klinische Forschung

Related research project(s)

IZKF-J63 (M1): The role of Interleukin-3 in experimental colitis and human inflammatory bowel disease Dec. 1, 2017 - Nov. 30, 2020

How to cite

APA:

Binder, M.-T., Becker, E., Wiendl, M., Schleier, L., Fuchs, F., Leppkes, M.,... Zundler, S. (2018). Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. Inflammatory Bowel Diseases, 24(6), 1237-1250. https://doi.org/10.1093/ibd/izy077

MLA:

Binder, Marie-Theres, et al. "Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s." Inflammatory Bowel Diseases 24.6 (2018): 1237-1250.

BibTeX: Download